Literature DB >> 2559352

Evidence for the involvement of the central adrenergic system in interleukin 1-induced adrenocortical response.

J Weidenfeld1, O Abramsky, H Ovadia.   

Abstract

The role of central catecholamines in the mediation of adrenocortical activation, induced by interleukin 1 (IL-1), was investigated by measuring ACTH and corticosterone in serum. Adult male rats were injected with either vehicle or the neurotoxin 6-hydroxydopamine (6-OHDA) into the lateral ventricle or the ventral noradrenergic ascending bundle. In vehicle-injected rats, 2 U of IL-1, injected intraventricularly, produced a 5- and 15-fold increase in ACTH and CS, respectively, in serum, 120 min after the injection of IL-1. In contrast, 6-OHDA, injected either intraventricularly or into the ventral noradrenergic ascending bundle, abolished the response to an intracerebral injection of IL-1. In addition, in rats pretreated with the alpha 1-adrenergic antagonist, prazosin, IL-1 failed to activate the adrenocortical axis. In other rats pretreated with the beta-adrenergic antagonist, propranolol, the adrenocortical response did not significantly differ from that of vehicle-pretreated rats. These results suggest that central adrenergic transmission, originating at the ventral noradrenergic ascending bundle and acting through alpha 1-adrenergic receptors, is involved in the adrenocortical response to IL-1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559352     DOI: 10.1016/0028-3908(89)90018-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1.

Authors:  A Ericsson; C Arias; P E Sawchenko
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

2.  Deletion of the ventral noradrenergic bundle obliterates the early ACTH response after systemic LPS, independently from the plasma IL-1β surge.

Authors:  L Givalois; S Gaillet; M Mekaouche; C Ixart; A F Bristow; P Siaud; A Szafarczyk; F Malaval; I Assenmacher; G Barbanel
Journal:  Endocrine       Date:  1995-07       Impact factor: 3.633

3.  [Interleukin-1 receptors in the central nervous system: role in infection and in stress].

Authors:  F Haour; C Marquette; E Ban; M Crumeyrolle-Arias; G Fillion
Journal:  J Psychiatry Neurosci       Date:  1995-11       Impact factor: 6.186

4.  Mechanisms of the effect of Icv IL-1β on oxytocin release in the anesthetized, lactating rat.

Authors:  B C Wilson; K Fulop; A J Summerlee
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

Review 5.  Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis.

Authors:  N Barkhudaryan; A J Dunn
Journal:  Neurochem Res       Date:  1999-09       Impact factor: 3.996

Review 6.  Attenuated hypothalamo-pituitary-adrenal axis responses to immune challenge during pregnancy: the neurosteroid opioid connection.

Authors:  Paula J Brunton; John A Russell
Journal:  J Physiol       Date:  2007-11-08       Impact factor: 5.182

Review 7.  Role of interleukin-1 in stress responses. A putative neurotransmitter.

Authors:  F Shintani; T Nakaki; S Kanba; R Kato; M Asai
Journal:  Mol Neurobiol       Date:  1995-02       Impact factor: 5.590

8.  Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins.

Authors:  M Ek; M Kurosawa; T Lundeberg; A Ericsson
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

9.  Effects of cytokines and infections on brain neurochemistry.

Authors:  Adrian J Dunn
Journal:  Clin Neurosci Res       Date:  2006-08

10.  Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol.

Authors:  M Maes; E Bosmans; H Y Meltzer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.